KRYS · NASDAQ
Krystal Biotech (KRYS) Stock Price & Fundamentals
Krystal Biotech (KRYS) closed at $352.38 on Oct 9, 2026, up 0.82% from the previous close of $349.52.
Share price, past year
1Y +27.54%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $352.38 |
| Sep 30, 2026 | $349.84 |
| Aug 31, 2026 | $328.39 |
| Jul 31, 2026 | $310.88 |
| Jun 30, 2026 | $296.24 |
| May 29, 2026 | $280.21 |
| Apr 30, 2026 | $284.90 |
| Mar 31, 2026 | $272.54 |
| Feb 27, 2026 | $274.66 |
| Jan 30, 2026 | $275.32 |
| Dec 31, 2025 | $277.56 |
| Nov 28, 2025 | $271.72 |
| Oct 31, 2025 | $263.57 |
Key statistics
- Market cap
- $10.43B
- P/E (TTM)
- 44.2
- EPS (TTM)
- $7.97
- Revenue (TTM)
- $440.48M
- Net income (TTM)
- $241.47M
- Shares outstanding
- 29.6M
- Dividend yield
- —
- 52-week range
- $260.29 – $353.76
Krystal Biotech's market cap is $10.43B, based on a share price of $352.38 and 29.6M shares outstanding as of Jun 30, 2026.
Financials
Krystal Biotech reported revenue of $389.13M for fiscal 2025, up 33.94% from fiscal 2024.
Krystal Biotech earned net income of $204.83M in fiscal 2025, a net margin of 52.6%.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $389.13M | +33.9% | $204.83M | 52.6% | $6.84 | $188.91M |
| FY2024ended Dec 31, 2024 | $290.52M | +473.0% | $89.16M | 30.7% | $3.00 | $119.18M |
| FY2023ended Dec 31, 2023 | $50.70M | — | $10.93M | 21.6% | $0.39 | −$100.60M |
| FY2022ended Dec 31, 2022 | $0.00 | — | −$139.98M | — | −$5.49 | −$153.55M |
| FY2021ended Dec 31, 2021 | $0.00 | — | −$69.57M | — | −$3.13 | −$116.27M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $119.22M | $54.77M | $1.79 |
| Q1 FY2026ended Mar 31, 2026 | $116.36M | $55.93M | $1.83 |
| Q4 FY2025ended Dec 31, 2025 | $107.11M | $51.40M | $1.69 |
| Q3 FY2025ended Sep 30, 2025 | $97.80M | $79.37M | $2.66 |
| Q2 FY2025ended Jun 30, 2025 | $96.04M | $38.33M | $1.29 |
| Q1 FY2025ended Mar 31, 2025 | $88.18M | $35.73M | $1.20 |
| Q4 FY2024ended Dec 31, 2024 | $91.14M | $45.48M | $1.53 |
| Q3 FY2024ended Sep 30, 2024 | $83.84M | $27.18M | $0.91 |
Company profile
- Name
- Krystal Biotech, Inc.
- Ticker
- KRYS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 2100 Wharton Street, Suite 701, Pittsburgh, PA 15203
- Fiscal year ends
- December
- SEC CIK
- 0001711279
Recent SEC filings
- Aug 3, 2026
- Aug 3, 2026
- Jul 21, 2026
- May 20, 2026
- May 4, 2026
- May 4, 2026
- Feb 17, 2026
- Feb 17, 2026
Frequently asked questions
What is Krystal Biotech's stock price?
Krystal Biotech (KRYS) closed at $352.38 on Oct 9, 2026, up 0.82% from the previous close of $349.52.
What is Krystal Biotech's market cap?
Krystal Biotech's market cap is $10.43B, based on a share price of $352.38 and 29.6M shares outstanding as of Jun 30, 2026.
How much revenue does Krystal Biotech make?
Krystal Biotech reported revenue of $389.13M for fiscal 2025, up 33.94% from fiscal 2024.
What is KRYS's P/E ratio?
Krystal Biotech's price-to-earnings ratio is 44.2, based on trailing twelve-month diluted EPS of $7.97.
Does Krystal Biotech pay a dividend?
Krystal Biotech's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Krystal Biotech, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures